Hawai'i-Pacific Chapter
A quarterly e-newsletter for the Hawai'i Pacific Chapter of ACHE Spring Issue
In This Issue
Message from your ACHE Regent, Spring 2015
Message from the Chapter President
Guam Local Program Council
Recent Chapter Events
News from the Education Committee
Membership: New Fellows, Members, and Recertified Fellows
Spring 2015 Calendar of Events
Spring 2015 Education Calendar
Spring 2015 Financial Report
Reflections on Diversity Within our Chapter
Risk of Infection from Contaminated Duodenoscopes
National News - Spring 2015
Five Methods to Engage a New Employee
Eliminate These Poor Listening Habits
Many thanks to our Sponsors!
Ensure delivery of Chapter E-newsletter (Disclaimer)
Newsletter Tools
Search Past Issues
Print-Friendly Article
Print-Friendly Issue
Forward to a Friend
What topic interests you most as an ACHE member and health care leader?
Leadership and Governance
Diversity and Inclusion
Advances in Delivery of Care
FACHE Credentialling Resources and Exam Preparation
Industry Updates


Coral Andrews, FACHE

Darlena Chadwick, FACHE

Gidget Ruscetta, FACHE

LT Joseph Fromknecht


Selma Yamamoto

Natalie Pagoria

Art Gladstone, FACHE
Micah Ewing, MBA

MAJ Charlotte Hildebrand, FACHE

Lt. John Piccone

Nick Hughey

Jennifer Dacumos

Stella Laroza


Martha Smith, FACHE


Risk of Infection from Contaminated Duodenoscopes
Richard Giardina RN, MPH, CIC

Over the past seven years, at least seven hospitals have reported outbreaks of carbapenem-resistant Enterobacteriaceae (CRE) bacterial infections associated with duodenoscopes used for Endoscopic Retrograde Cholangiopancreatography (ERCP) procedures. ERCP procedures are used to treat and diagnose a variety of conditions of the gall bladder and pancreas, including ductal obstructions, stones, and malignancy. (1) In total, from January 2013 through December 2014, the FDA received 75 medical device reports encompassing approximately 135 patients in the United States relating to possible microbial transmission from reprocessed duodenoscopes. It is possible that not all cases have been reported to the FDA.(2). There have been fatalities associated with CRE infection in some of these patients.


FDA has received inquiries from healthcare providers about whether they should cancel ERCP procedures, based on the fact that one specific model duodenoscope manufactured by Olympus (the TJF-Q180V) does not currently have a 510(k) clearance. FDA is not recommending that healthcare providers cancel ERCP procedures for their patients who need them.


Olympus has a pending 510(k) application for this device, and the company continues to market the product while the application is under review. FDA is not taking action against Olympus regarding its device during the review of the application, because, based on the information currently available to the Agency, it is felt that that removal of the device from the market could lead to an insufficient number of available duodenoscopes to meet the clinical demand in the United States of approximately 500,000 procedures per year


The FDA’s analysis indicates that the reported duodenoscope-associated infections have occurred in patients who have had procedures with duodenoscopes from all three manufacturers. At this time, FDA has no evidence that the lack of a 510(k) clearance was associated with the infections.


FDA recommends the following:

·        Thoroughly clean and disinfect duodenoscopes, pursuant to the manufacturers’ instructions;

·        Have a comprehensive quality program in place for reprocessing duodenoscopes;

·        If you suspect that a duodenoscope may be associated with a patient infection, take it out of service and meticulously clean and disinfect it until it is verified to be free of pathogens;

·        Inform patients of the benefits and risks associated with ERCP procedures, including the risk of possible infection;

·        Physicians should discuss with their patients what they should expect following the ERCP procedure and what symptoms (such as fever or chills, chest pain, severe abdominal pain, trouble swallowing or breathing, nausea and vomiting, or black or tarry stools) should prompt additional follow-up;

·        Submit a report to the manufacturer and to the FDA via MedWatch if you suspect problems have led to patient infections.


The CDC has published an interim protocol for culturing duodenoscopes on their website.  You can access the protocol by clicking here: http://www.cdc.gov/hai/organisms/cre/cre-duodenoscope-surveillance-protocol.html


1.https://www.ecri.org/Resources/Superbug/Culturing_Duodenoscopes_Key_Step_to_Reducing_CRE_Infections.pdf, accessed 3/19/15

2. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm434871.htm, accessed 3/19/15


Previous Article
Next Article
Related News Related News
Save the Date

Spring Chapter Mingle

We will be having a chapter social event in May.  Stay tuned for more information on this event and take advantage of this opportunity to get to know your chapter officers and members.  Please feel free to bring a colleague who might be interested in joining our Chapter!  

Hawaii Financial Management Association (HFMA) Annual Conference

April 9-10 at the Ala Moana Hotel.  Focus is on the Affordable Care Act and Leadership into the future.  More details at www.hawaiihfma.org



This e-mail was sent from the American College of Healthcare Executives, 1 North Franklin Street, Suite 1700, Chicago, IL  60606-3529